Wall Avenue provide-side analysts are beneficial about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even nevertheless their holdings have misplaced much more than fifty nine% in excess of the past 52 weeks. These two “falling knives” have acquired acquire tips score on Wall Avenue.

Because the deep downturn in the share rates could be a signal of lasting complications, obtaining shares of falling knives implies a significant danger of reduction. Buyers can reduce the danger by choosing falling knives whose harmony sheets have reduce financial debt.

Consequently, investors might want to think about the adhering to falling knives, as they have moderate-to-very low financial debt-to-equity ratios.

Ekso Bionics Holdings Inc

Shares of Ekso Bionics Holdings traded at a rate of $3.13 per unit at shut on Friday for a sector cap of $18.29 million. The inventory rate fell by 89% in excess of the past 52 weeks by means of Might 15.

At this time, the share rate represents an eighty three.3% price cut to the center position of the 52-7 days selection of $2.twenty five to $35.thirty. The 14-day relative energy index of forty two signifies that the share rate however trades much from oversold stages, even with the share rate plunge.

Ekso Bionics Holdings is a Richmond, California-centered designer and seller of exoskeletons for use in various industries worldwide, such as health care and armed forces. The company has a moderate financial debt-to-equity ratio of .sixty one. The Altman Z-rating of -14.seventy eight, which is much less than 1.81, signifies that the company could be in distress zones. However, the Piotroski F-Score of five out of 9 suggests stability.

Wall Avenue provide-side analysts endorse a acquire score and forecast that the share rate of Ekso Bionics Holdings Inc will bounce back up to a concentrate on rate of $15 per share, symbolizing a 379% upside from Friday’s closing rate.

Entasis Therapeutics Holdings Inc

Shares of Entasis Therapeutics Holdings traded at a rate of $2.forty six per unit at shut on Might 15 for a sector cap of $39.ninety five million. The inventory rate has fallen by almost sixty two% in excess of the past 52 weeks by means of Might five.

At this time, the share rate trades at a 38.five% price cut to the center position of the 52-7 days selection of $1.75 to $9.twenty five. The 14-day relative energy index of forty one tells us that the share rate is however much from oversold stages, even with the sharp share rate depreciation.

Entasis Therapeutics Holdings is a Waltham, Massachusetts-centered medical-phase biopharmaceutical developer of novel antibacterial products and solutions to handle major multi-drug resistant gram-negative bacterial bacterial infections. Entasis Therapeutics Holdings’ very low financial debt-to-equity ratio of .06 (compared to the marketplace median of .1) mitigates the Altman Z-Score of -6.13 (much less than 1.81), which implies that the company could encounter individual bankruptcy.

Wall Avenue provide-side analysts forecast that the share rate of Entasis Therapeutics Holdings will bounce back up to a concentrate on rate of $6.twenty five per share, reflecting a 154% upside from Friday’s closing rate.

Disclosure: I have no positions in any securities stated.

Read much more listed here:

Not a Premium Member of GuruFocus? Signal up for a free seven-day demo listed here.